{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T11:25:18Z","timestamp":1790508318594,"version":"4.1.0"},"reference-count":176,"publisher":"Informa UK Limited","issue":"10","content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Critical Reviews in Toxicology"],"published-print":{"date-parts":[[2018,11,26]]},"DOI":"10.1080\/10408444.2018.1553935","type":"journal-article","created":{"date-parts":[[2019,2,22]],"date-time":"2019-02-22T18:10:08Z","timestamp":1550859008000},"page":"815-838","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":13,"title":["Definitive urine drug testing in office-based opioid treatment: a literature review"],"prefix":"10.1080","volume":"48","author":[{"given":"Andrea G.","family":"Barthwell","sequence":"first","affiliation":[{"name":"Encounter Medical Group, Oak Park, IL, USA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey","family":"Allgaier","sequence":"additional","affiliation":[{"name":"PLLC, Ideal Option, Kennewick, WA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenneth","family":"Egli","sequence":"additional","affiliation":[{"name":"PLLC, Ideal Option, Kennewick, WA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2019,2,22]]},"reference":[{"key":"CIT0001","volume-title":"Report 1 of the council on science and public health (I-16) Urine Drug Testing","author":"[AMA] American Medical Association","year":"2016"},{"key":"CIT0002","volume-title":"Interagency guideline on prescribing opioids for pain","author":"[AMDG] Washington State Agency Medical Directors\u2019 Group","year":"2015"},{"key":"CIT0003","doi-asserted-by":"publisher","DOI":"10.1176\/appi.books.9780890425596"},{"key":"CIT0004","volume-title":"National practice guideline for the use of medications in the treatment of addiction involving opioid use","author":"[ASAM] American Society of Addiction Medicine.","year":"2015"},{"key":"CIT0005","doi-asserted-by":"publisher","DOI":"10.1007\/978-1-4419-0338-9_23"},{"key":"CIT0007","doi-asserted-by":"publisher","DOI":"10.1080\/10550887.2010.509273"},{"key":"CIT0008","doi-asserted-by":"publisher","DOI":"10.4103\/0976-500X.136106"},{"key":"CIT0009","doi-asserted-by":"publisher","DOI":"10.1080\/13556219971885"},{"key":"CIT0010","doi-asserted-by":"publisher","DOI":"10.3109\/10826084.2015.1135953"},{"key":"CIT0011","volume-title":"Drug testing: a white paper of the American Society of Addiction Medicine (ASAM)","author":"Barthwell AG","year":"2013"},{"key":"CIT0012","unstructured":"Barthwell AG, Baxter L, Krause M, Rustin T, Kottenstette C, Fremd T, Fudin J, Dole E, Brown A. 2015. The statement of consensus on the proper utilization of urine testing in identifying and treating substance use disorders."},{"key":"CIT0013","doi-asserted-by":"publisher","DOI":"10.1038\/mp.2008.90"},{"key":"CIT0014","doi-asserted-by":"publisher","DOI":"10.1196\/annals.1441.031"},{"key":"CIT0015","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpba.2013.05.026"},{"key":"CIT0016","first-page":"9","volume":"8","author":"Bey T","year":"2007","journal-title":"Cal J Emerg Med"},{"key":"CIT0017","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0104275"},{"key":"CIT0018","doi-asserted-by":"publisher","DOI":"10.1002\/phar.1187"},{"key":"CIT0021","volume-title":"Date rape drug metabolite: NMR reveals evidence next day","author":"Bradley D","year":"2017"},{"key":"CIT0022","doi-asserted-by":"publisher","DOI":"10.1007\/s40268-017-0207-7"},{"key":"CIT0023","doi-asserted-by":"publisher","DOI":"10.1037\/1064-1297.4.4.396"},{"key":"CIT0024","doi-asserted-by":"publisher","DOI":"10.2174\/1570159X13666141210215423"},{"key":"CIT0025","doi-asserted-by":"publisher","DOI":"10.1016\/0091-3057(94)90339-5"},{"key":"CIT0026","first-page":"26","volume":"261","author":"Carroll M","year":"1992","journal-title":"J Pharmacol Exp Ther"},{"key":"CIT0162","unstructured":"[CBHSQ] Center for Behavioral Health Statistics and Quality. 2012. The TEDS report: admissions reporting benzodiazepine and narcotic pain reliever abuse at treatment entry. Rockville (MD): Substance Abuse and Mental Health Services Administration."},{"key":"CIT0019","unstructured":"[CBHSQ] Center for Behavioral Health Statistics and Quality. 2016. Key substance use and mental health indicators in the United States: Results from the 2015 National Survey on Drug Use and Health (HHS Publication No. SMA 16-4984, NSDUH Series H-51). http:\/\/www.samhsa.gov\/data\/."},{"key":"CIT0070","unstructured":"[CBHSQ] Center for Behavioral Health Statistics and Quality. 2015. Behavioral health trends in the United States: Results from the 2014 National Survey on Drug Use and Health (HHS Publication No. SMA 15-4927, NSDUH Series H-50). Rockville (MD): Center for Behavioral Health Statistics and Quality. http:\/\/www.samhsa.gov\/data\/."},{"key":"CIT0182","unstructured":"[CESAR] Center for Substance Abuse Research. 2013. Flunitrazepam (Rohypnol). College Park (MD): Center for Substance Abuse Research. [accessed 2018 December 28]. http:\/\/www.cesar.umd.edu\/cesar\/drugs\/rohypnol.asp#30."},{"key":"CIT0029","volume-title":"Amphetamines","author":"CESAR","year":"2017"},{"key":"CIT0030","doi-asserted-by":"publisher","DOI":"10.1186\/1471-244X-11-90"},{"key":"CIT0031","doi-asserted-by":"publisher","DOI":"10.1046\/j.1360-0443.2003.00376.x"},{"key":"CIT0032","author":"Craven C","year":"2014","journal-title":"Pract Pain Manag"},{"key":"CIT0033","volume-title":"The adverse effects of marijuana (for healthcare professionals)","author":"[CSAM] California Society of Addiction Medicine","year":"2018"},{"key":"CIT0027","volume-title":"Clinical guidelines for the use of buprenorphine in the treatment of opioid addiction","author":"[CSAT] Center for Substance Abuse Treatment.","year":"2004"},{"key":"CIT0148","unstructured":"[CSAT] Center for Substance Abuse Treatment. 1999. Treatment for stimulant use disorders. Rockville (MD): Substance Abuse and Mental Health Services Administration (US). Treatment Improvement Protocol (TIP) Series, No. 33. 2 How stimulants affect the brain and behavior.https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK64333\/."},{"key":"CIT0105","unstructured":"[CSAT] Center for Substance Abuse Treatment. 2004. Clinical guidelines for the use of buprenorphine in the treatment of opioid addiction. Rockville (MD): Substance Abuse and Mental Health Services Administration (US). Treatment Improvement Protocol (TIP) Series, No. 40. 2 Pharmacology. https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK64236\/"},{"key":"CIT0149","unstructured":"CSAT. 2006 Clinical issues in intensive outpatient treatment. Rockville (MD): Substance Abuse and Mental Health Services Administration (US). Treatment Improvement Protocol (TIP) Series, No. 47. https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK64093\/"},{"key":"CIT0151","unstructured":"CSAT. 2008. Medication-assisted treatment for opioid addiction in opioid treatment programs. Rockville (MD): Substance Abuse and Mental Health Services Administration (US). Treatment Improvement Protocol (TIP) Series, No. 43. https:\/\/store.samhsa.gov\/shin\/content\/SMA09-4341\/SMA09-4341.pdf."},{"key":"CIT0034","doi-asserted-by":"publisher","DOI":"10.1046\/j.1360-0443.2001.96574910.x"},{"key":"CIT0035","first-page":"359","volume":"17","author":"Darragh A","year":"2014","journal-title":"Pain Physician"},{"key":"CIT0036","volume-title":"What are the uses of ketamine","author":"Davis K","year":"2017"},{"key":"CIT0037","volume-title":"Benzodiazepines","author":"[DEA] Drug Enforcement Administration","year":"2013"},{"key":"CIT0038","volume-title":"Drugs of abuse: a DEA resource Guide","author":"DEA.","year":"2017"},{"key":"CIT0039","volume-title":"Controlled substance schedules","author":"DEA.","year":"2018"},{"key":"CIT0040","doi-asserted-by":"publisher","DOI":"10.1016\/S0376-8716(02)00017-0"},{"key":"CIT0041","doi-asserted-by":"publisher","DOI":"10.5055\/jom.2015.0248"},{"key":"CIT0042","doi-asserted-by":"publisher","DOI":"10.1093\/jat\/34.8.444"},{"key":"CIT0043","doi-asserted-by":"publisher","DOI":"10.1016\/S0376-8716(02)00243-0"},{"key":"CIT0044","doi-asserted-by":"publisher","DOI":"10.1080\/02791072.2012.660106"},{"key":"CIT0045","author":"DuPont R","year":"2013","journal-title":"American Society of Addiction Medicine (ASAM)"},{"key":"CIT0046","doi-asserted-by":"publisher","DOI":"10.1002\/dta.1633"},{"key":"CIT0047","doi-asserted-by":"publisher","DOI":"10.1186\/1752-1947-5-167"},{"key":"CIT0048","volume-title":"Sedative, hypnotic, anxiolytic use disorders","author":"Erlach SP","year":"2017"},{"key":"CIT0049","doi-asserted-by":"publisher","DOI":"10.1097\/ADT.0b013e31826d1dda"},{"key":"CIT0050","doi-asserted-by":"publisher","DOI":"10.1007\/BF03161224"},{"key":"CIT0051","unstructured":"FDA and Marijuana. 2018. Silver Spring (MD): U.S. Food & Drug Administration. [accessed 2018 December 20]. https:\/\/www.fda.gov\/NewsEvents\/PublicHealthFocus\/ucm421163.htm."},{"key":"CIT0052","volume-title":"Cesamet\u2122","author":"[FDA] U.S. Food & Drug Administration","year":"2006"},{"key":"CIT0053","volume-title":"FDA drug safety communication: FDA urges caution about withholding opioid addiction medications from patients taking bezodiazapines or CNS depressants: careful medication management can reduce risks","author":"FDA","year":"2017"},{"key":"CIT0054","first-page":"2619","volume":"69","author":"Gahlinger PM","year":"2004","journal-title":"Am Fam Physician"},{"key":"CIT0055","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0089031"},{"key":"CIT0056","doi-asserted-by":"publisher","DOI":"10.1007\/s12245-010-0235-3"},{"key":"CIT0057","doi-asserted-by":"publisher","DOI":"10.1520\/JFS14742J"},{"key":"CIT0058","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1002396"},{"key":"CIT0059","doi-asserted-by":"publisher","DOI":"10.1093\/alcalc\/agh260"},{"key":"CIT0060","doi-asserted-by":"publisher","DOI":"10.2174\/1874205X01206010018"},{"key":"CIT0061","doi-asserted-by":"publisher","DOI":"10.3109\/00952999709001685"},{"key":"CIT0062","doi-asserted-by":"publisher","DOI":"10.3810\/pgm.2013.07.2684"},{"key":"CIT0063","doi-asserted-by":"publisher","DOI":"10.1007\/s13181-013-0292-0"},{"key":"CIT0064","volume-title":"A clinical guide to urine drug testing: augmenting paint management & enhancing patient care","author":"Hammett-Stabler C","year":"2008"},{"key":"CIT0065","doi-asserted-by":"publisher","DOI":"10.1001\/jamapsychiatry.2014.436"},{"key":"CIT0066","volume-title":"Neonatal jaundice medication","author":"Hansen TWR","year":"2017"},{"key":"CIT0067","volume-title":"Benzodiazepines (and the alternatives)","author":"Harvard Health Publishing","year":"2014"},{"key":"CIT0068","volume-title":"Substance abuse (depressants or sedative-hypnotic drugs)","author":"Harvard Health Publishing","year":"2014"},{"key":"CIT0069","first-page":"85","volume":"30","author":"Hattab EM","year":"2000","journal-title":"Ann Clin Lab Sci"},{"key":"CIT0071","doi-asserted-by":"publisher","DOI":"10.1002\/dta.1464"},{"key":"CIT0072","doi-asserted-by":"publisher","DOI":"10.1093\/alcalc\/agn084"},{"key":"CIT0073","doi-asserted-by":"publisher","DOI":"10.1093\/jat\/32.7.516"},{"key":"CIT0074","doi-asserted-by":"publisher","DOI":"10.17756\/jrdsas.2016-025"},{"key":"CIT0075","doi-asserted-by":"publisher","DOI":"10.1097\/ADM.0000000000000323"},{"key":"CIT0076","doi-asserted-by":"publisher","DOI":"10.4103\/0253-7176.130960"},{"key":"CIT0077","volume-title":"Ketalar \u2013 ketamine hydrochloride injection","author":"JHP Pharmaceuticals, LLC","year":"2012"},{"key":"CIT0078","doi-asserted-by":"publisher","DOI":"10.1093\/jat\/bkv133"},{"key":"CIT0079","doi-asserted-by":"crossref","unstructured":"Jones H. 2004. Practical considerations for the use of buprenorphine. Farmington (CT): National Alliance of Advocates for Buprenorphine Treatment. [accessed 2018 May 23] https:\/\/www.naabt.org\/documents\/Practical_Conciderations%20.pdf.","DOI":"10.1151\/spp04224"},{"key":"CIT0080","doi-asserted-by":"publisher","DOI":"10.1016\/j.amepre.2015.03.040"},{"key":"CIT0081","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2012.07.004"},{"key":"CIT0082","first-page":"67","volume":"2015","author":"Kaabneh MAF","year":"2015","journal-title":"Clin Med Insights Pediatr"},{"key":"CIT0083","doi-asserted-by":"publisher","DOI":"10.1097\/ADM.0000000000000166"},{"key":"CIT0084","doi-asserted-by":"publisher","DOI":"10.1097\/FTD.0b013e3182690127."},{"key":"CIT0085","doi-asserted-by":"publisher","DOI":"10.1097\/AJP.0b013e318125c5e8"},{"key":"CIT0086","doi-asserted-by":"publisher","DOI":"10.2105\/AJPH.2012.300989"},{"key":"CIT0087","first-page":"61","volume":"11","author":"Kirsh KL","year":"2015","journal-title":"J Opioid Manag"},{"key":"CIT0088","doi-asserted-by":"publisher","DOI":"10.1016\/0740-5472(90)90005-B"},{"key":"CIT0089","volume-title":"Risks of chronic hypnotic use. Madame curie bioscience database [Internet]","author":"Kripke DF"},{"key":"CIT0090","first-page":"160","volume":"6","author":"Lamonica AK","year":"2012","journal-title":"J Ethnogr Qual Res"},{"key":"CIT0091","doi-asserted-by":"publisher","DOI":"10.1192\/pb.39.1.50"},{"key":"CIT0092","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2008.07.017"},{"key":"CIT0094","doi-asserted-by":"publisher","DOI":"10.1016\/j.cca.2012.10.023"},{"key":"CIT0095","doi-asserted-by":"publisher","DOI":"10.1093\/jat\/34.3.149"},{"key":"CIT0096","doi-asserted-by":"publisher","DOI":"10.1080\/00952990902933860"},{"key":"CIT0097","doi-asserted-by":"publisher","DOI":"10.1111\/j.1465-3362.2010.00271.x"},{"key":"CIT0098","doi-asserted-by":"publisher","DOI":"10.1016\/j.jfma.2017.04.008"},{"key":"CIT0099","doi-asserted-by":"publisher","DOI":"10.1097\/ADM.0000000000000045"},{"key":"CIT0100","doi-asserted-by":"publisher","DOI":"10.1016\/0091-3057(94)90338-7"},{"key":"CIT0102","volume-title":"Barbiturate (oral route, parenteral route, rectal route)","author":"Mayo Clinic.","year":"2017"},{"key":"CIT0103","doi-asserted-by":"publisher","DOI":"10.1111\/j.1521-0391.2009.00005.x"},{"key":"CIT0104","doi-asserted-by":"publisher","DOI":"10.1093\/jat\/bkr020"},{"key":"CIT0106","doi-asserted-by":"publisher","DOI":"10.1093\/jat\/bks003"},{"key":"CIT0107","doi-asserted-by":"publisher","DOI":"10.1038\/sj.npp.1301319"},{"key":"CIT0108","doi-asserted-by":"publisher","DOI":"10.1177\/00333549111260S115"},{"key":"CIT0109","doi-asserted-by":"publisher","DOI":"10.1016\/j.jsat.2017.01.005"},{"key":"CIT0110","doi-asserted-by":"publisher","DOI":"10.4065\/83.1.66"},{"key":"CIT0111","doi-asserted-by":"publisher","DOI":"10.1016\/j.pbb.2011.06.032"},{"key":"CIT0112","unstructured":"[AMA] American Medical Association. 2016. Report 1 of the council on science and public health (I-16): Urine drug testing. Chicago (IL): American Medical Association."},{"key":"CIT0113","volume-title":"Mass spectrometry for the clinical laboratory","author":"Nair H","year":"2016"},{"key":"CIT0114","volume-title":"PCP fast facts","author":"[NDIC] National Drug Intelligence Center","year":"2003"},{"key":"CIT0115","volume-title":"Rohypnol fast facts","author":"NDIC","year":"2003"},{"key":"CIT0116","volume-title":"Monitoring the future 2016 survey results","author":"[NIDA] National Institute on Drug Abuse","year":"2016"},{"key":"CIT0117","volume-title":"What are the short-term effects of cocaine abuse","author":"NIDA","year":"2016"},{"key":"CIT0118","volume-title":"What is cocaine","author":"NIDA","year":"2016"},{"key":"CIT0119","volume-title":"MDMA (ecstasy) abuse","author":"NIDA","year":"2017"},{"key":"CIT0120","volume-title":"Opioids","author":"NIDA","year":"2017"},{"key":"CIT0121","volume-title":"Overdose Death Rates","author":"NIDA","year":"2017"},{"key":"CIT0122","volume-title":"Commonly abused drugs charts (Bath Salts)","author":"NIDA","year":"2018"},{"key":"CIT0123","volume-title":"Commonly abused drugs charts (GHB)","author":"NIDA","year":"2018"},{"key":"CIT0124","volume-title":"Treatment approaches for drug addiction","author":"NIDA","year":"2018"},{"key":"CIT0125","volume-title":"What is marijuana","author":"NIDA","year":"2018"},{"key":"CIT0126","volume-title":"Urine drug testing for pain management","author":"NIDA","year":"2018"},{"key":"CIT0127","first-page":"ES119","volume":"15","author":"Owen GT","year":"2012","journal-title":"Pain Physician"},{"key":"CIT0193","unstructured":"Palmetto GBA. 2018. Local Coverage Determination (LCD): Controlled Substance Monitoring and Drugs of Abuse Testing (L5724). Columbia (SC): Palmetto GBA."},{"key":"CIT0128","volume-title":"Ketamine","author":"Partnership for Drug-Free Kids","year":"2018"},{"key":"CIT0129","unstructured":"Passik S, Heit H, Rzetelny A, Pesce A, Mikel C, Kirsh K. 2013. Trends in drug and illicit use from urine drug testing from addiction treatment clients. Proceedings of the International Conference on Opioids. ASAM White Paper, Boston (MA)."},{"key":"CIT0130","first-page":"283","volume":"13","author":"Pesce A","year":"2010","journal-title":"Pain Physician"},{"key":"CIT0131","doi-asserted-by":"publisher","DOI":"10.1111\/j.1526-4637.2012.01350.x"},{"key":"CIT0132","first-page":":003","volume":"5","author":"Pesce A","year":"2012","journal-title":"J Anal Bioanal Tech"},{"key":"CIT0133","doi-asserted-by":"publisher","DOI":"10.1037\/0022-006X.73.2.354"},{"key":"CIT0134","doi-asserted-by":"publisher","DOI":"10.2147\/SAR.S20895"},{"key":"CIT0135","doi-asserted-by":"publisher","DOI":"10.1007\/s13181-011-0193-z"},{"key":"CIT0136","volume-title":"NDA 20-733 Suboxone (buprenorphine and naloxone) sublingual tablet CIII buprenorphine (opioid partial agonist-antagonist) naloxone (opioid antagonist)","author":"Reckitt Benckiser Pharmaceuticals Inc","year":"2011"},{"key":"CIT0137","doi-asserted-by":"publisher","DOI":"10.1111\/j.1526-4637.2009.00726.x"},{"key":"CIT0138","doi-asserted-by":"publisher","DOI":"10.4155\/bio.09.81"},{"key":"CIT0139","first-page":"301","volume":"37","author":"Reisfield GM","year":"2007","journal-title":"Ann Clin Lab Sci"},{"key":"CIT0141","first-page":"102","volume":"1","author":"Riahi-Zanjani B","year":"2014","journal-title":"Pharmacologyonline"},{"key":"CIT0142","unstructured":"Richards JR, Laurin EG. 2018. Cocaine. StatPearls [Internet].Treasure Island (FL): StatPearls Publishing. https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK430769\/."},{"key":"CIT0143","doi-asserted-by":"publisher","DOI":"10.1186\/1477-7517-8-31"},{"key":"CIT0144","first-page":"188","volume":"4","author":"Ruan X","year":"2015","journal-title":"J Pain Relief"},{"key":"CIT0145","doi-asserted-by":"publisher","DOI":"10.15585\/mmwr.mm655051e1"},{"key":"CIT0146","doi-asserted-by":"publisher","DOI":"10.1007\/s11469-015-9569-7"},{"key":"CIT0147","doi-asserted-by":"publisher","DOI":"10.1093\/jat\/bku075"},{"key":"CIT0183","unstructured":"SAMHSA Substance Abuse and Mental Health Services Administration, Center for Behavioral Health Statistics and Quality. 2014. The DAWN Report: Benzodiazepines in Combination with Opioid Pain Relievers or Alcohol: Greater Risk of More Serious ED Visit Outcomes. Rockville (MD): Substance Abuse and Mental Health Services Administration, Center for Behavioral Health Statistics and Quality."},{"key":"CIT0093","unstructured":"[SAMHSA] Substance Abuse and Mental Health Services Administration. 2012. Pharmacologic guidelines for treating individuals with post-traumatic stress disorder and co-occurring opioid use disorders (HHS Publication No. SMA-12-4688). Rockville (MD): Substance Abuse and Mental Health Services Administration."},{"key":"CIT0152","volume-title":"The DAWN report: emergency department visits involving phencyclidine (PCP)","author":"SAMHSA","year":"2013"},{"key":"CIT0153","volume-title":"Medication and counseling treatment","author":"SAMHSA","year":"2015"},{"key":"CIT0154","volume-title":"Buprenorphine","author":"SAMHSA","year":"2016"},{"key":"CIT0155","volume-title":"Results from the 2016 Capitalize National Survey on Drug Use and Health: detailed tables","author":"SAMHSA","year":"2016"},{"key":"CIT0156","doi-asserted-by":"publisher","DOI":"10.1016\/j.cll.2016.07.009"},{"key":"CIT0158","doi-asserted-by":"publisher","DOI":"10.1089\/can.2017.0006"},{"key":"CIT0159","first-page":"SE1","volume":"20","author":"Snyder M","year":"2017","journal-title":"Pain Physician"},{"key":"CIT0160","first-page":"635","volume":"81","author":"Standridge JB","year":"2010","journal-title":"Am Fam Physician"},{"key":"CIT0161","doi-asserted-by":"publisher","DOI":"10.3109\/14659890903431603"},{"key":"CIT0163","unstructured":"SAMHSA 2013b. The DAWN report: emergency department visits involving phencyclidine (PCP). Rockville (MD): Substance Abuse and Mental Health Services Administration."},{"key":"CIT0164","unstructured":"SAMHSA. 2013c. Emergency department visits for adverse reactions involving the insomnia medication zolpidem. Rockville (MD): Substance Abuse and Mental Health Services Administration."},{"key":"CIT0165","doi-asserted-by":"publisher","DOI":"10.1111\/j.1521-0391.2009.00003.x"},{"key":"CIT0166","doi-asserted-by":"publisher","DOI":"10.1080\/08897077.2017.1356796"},{"key":"CIT0167","doi-asserted-by":"publisher","DOI":"10.1097\/01.jcp.0000237944.57893.28"},{"key":"CIT0168","volume-title":"The underestimated cost of the opioid crisis","author":"The Council of Economic Advisers","year":"2017"},{"key":"CIT0169","volume-title":"Medication-assisted treatment improves outcomes for patients with opioid use disorder","author":"The Pew Charitable Trusts","year":"2016"},{"key":"CIT0170","doi-asserted-by":"publisher","DOI":"10.1016\/j.pbb.2011.04.014"},{"key":"CIT0171","unstructured":"[AMA] American Medical Association. 2016. Report 1 of the council on science and public health (I-16): Urine drug testing. Chicago (IL): American Medical Association."},{"key":"CIT0172","doi-asserted-by":"publisher","DOI":"10.1007\/s11524-015-9967-y"},{"key":"CIT0173","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1402309"},{"key":"CIT0174","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1507771"},{"key":"CIT0175","doi-asserted-by":"publisher","DOI":"10.1016\/S0376-8716(98)00092-1"},{"key":"CIT0176","first-page":"40","volume":"23","author":"Weathermon R","year":"1999","journal-title":"Alcohol Res Health"},{"key":"CIT0177","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.g1996"},{"key":"CIT0178","doi-asserted-by":"publisher","DOI":"10.1016\/0091-3057(87)90576-4"},{"key":"CIT0179","volume-title":"Local coverage determination (LCD): drug testing (L34645)","author":"[WPSIC] Wisconsin Physicians Service Insurance Corporation","year":"2018"},{"key":"CIT0180","unstructured":"Yasgur BS. 2018. Gabapentin and opioids a potentially deadly combination. [accessed 2018 May 23]. Research: [about 4 screens]. https:\/\/www.painmedicinenews.com\/Clinical-Pain-Medicine\/Article\/03-18\/Gabapentin-and-Opioids-a-Potentially-Deadly-Combination\/47053?sub=C143BC655DA759D99E56383AE3C0C55ECB64ABF25DFEFEA185C6CA3F4F86B4&enl=true&lipi=urn:li:page:d_flagship3_feed;y0AoiQmuRTy3ozEhwaJ0iQ%3D%3D"}],"container-title":["Critical Reviews in Toxicology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/10408444.2018.1553935","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,9,7]],"date-time":"2020-09-07T02:01:05Z","timestamp":1599444065000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/10408444.2018.1553935"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,11,26]]},"references-count":176,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2018,11,26]]}},"alternative-id":["10.1080\/10408444.2018.1553935"],"URL":"https:\/\/doi.org\/10.1080\/10408444.2018.1553935","relation":{},"ISSN":["1040-8444","1547-6898"],"issn-type":[{"value":"1040-8444","type":"print"},{"value":"1547-6898","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,11,26]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=itxc20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=itxc20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2018-06-21","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-11-26","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-11-26","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-02-22","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}